Overall, PD-1/PD-L1 inhibitors did not show a survival benefit in most cancer types but were associated with a modestly improved survival benefit in patients with NSCLC, SCLC, melanoma and NPC. This evidence concerns the gene PDCD1 and small cell lung carcinoma.